Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.

Image credit: Komsan Loonprom/Shutterstock.com

The results of the Phase 2 trial were reported in Blood Cancer Journal. Of the 37 patients treated, 70% attained MRD negativity, with robust responses in both Philadelphia chromosome-positive and -negative disease. Patients who were treated earlier had the best outcomes. Relapse-free survival was 40 months, whereas median survival was 61 months.

Our results show that inotuzumab is highly effective at clearing residual disease in patients already in remission, with durable responses and encouraging survival. This approach has the potential to deepen remissions and change how we manage patients at high risk of relapse.

Elias Jabbour, MD, Study Principal Investigator and Professor, The University of Texas MD Anderson Cancer Center

What do the Trial Results Mean for Patients with B-cell ALL?

These findings imply that this ADC treatment may provide patients with a high likelihood of eradicating remaining disease, even if they have already received other therapies. Clearing MRD is a predictor of relapse in patients.

When MRD is eliminated and becomes undetectable, patients have a better probability of remaining in remission.  Furthermore, this treatment may assist patients in reaching the point where they are suitable for stem cell transplant or chimeric antigen receptor (CAR) T cell therapy in a safer, lower-disease state.

The treatment was well tolerated, and the adverse effects were controlled.

These results show inotuzumab as a promising treatment for deepening remissions and potentially improving long-term outcomes by eliminating residual leukemia.